[A19-98] Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.03.2020
Commission awarded on 29.11.2019 by the Federal Joint Committee (G-BA).
Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer if prior adjuvant trastuzumab-based therapy was completed less than one year ago
An advantage in the outcome "recurrence" is accompanied by major disadvantages in side effects during the treatment phase; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-40||Neratinib (breast cancer) - Addendum to Commission A19-98||Commission completed|